<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lung transplantation: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lung transplantation: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Lung transplantation: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ramsey R Hachem, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert M Kotloff, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Paul Dieffenbach, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 05, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Over the past 35 years, lung transplantation has become a viable treatment option for patients with a variety of end-stage lung diseases. The first human lung transplant procedure was performed in 1963, and the recipient survived 18 days, ultimately succumbing to renal failure and malnutrition [<a href="#rid1">1</a>]. Despite the outcome, this demonstrated that lung transplantation was technically feasible and that rejection could be averted with the available immunosuppressive agents, at least for a short time.</p><p>Over the ensuing 15 years, few lung transplant procedures were performed, and the majority of recipients died perioperatively because of bronchial anastomotic complications. However, in 1981, the first successful heart-lung transplantation was performed for idiopathic pulmonary arterial hypertension [<a href="#rid2">2</a>]. This was followed in 1983 by the first successful single lung transplantation for idiopathic pulmonary fibrosis [<a href="#rid3">3</a>] and in 1986 by the first double lung transplantation for emphysema [<a href="#rid4">4</a>]. These successes were attributed to improved surgical techniques and the advent of <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>. Over the following several years, the number of lung transplant procedures performed rapidly increased, and the operation became an accepted treatment for end-stage lung disease.</p><p>An overview of lung transplantation, including a discussion of outcomes, is presented here. Lung transplantation indications, recipient selection, choice of procedure, post-operative management and complications are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a> and  <a class="medical medical_review" href="/z/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management"</a> and  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/4655.html" rel="external">"Evaluation and treatment of acute cellular lung transplant rejection"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ACTIVITY</span><span class="headingEndMark"> — </span>There has been a steady growth in the number of lung transplant procedures performed annually since 2000, with approximately 4500 adult lung transplants reported annually since 2016 (<a class="graphic graphic_figure graphicRef71574" href="/z/d/graphic/71574.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. While part of this increase may be attributable to greater participation in the ISHLT Registry, the rapid rise in activity since 2005 suggests that the lung allocation system implemented in the US in 2005 has increased the number of transplants performed. In addition, the United States Organ Donation Breakthrough Collaborative, which began in 2003, increased organ donation and recovery by disseminating and implementing best practices across Collaborative hospitals [<a href="#rid6">6</a>].</p><p>A shortage of lung donors remains the major limiting factor to the number of transplants performed, despite a significant increase in the number of donors over the past decade [<a href="#rid7">7</a>]. Lung organ procurement rates from deceased donors have consistently been substantially lower than kidney, liver, and heart procurement rates. There is significant variability in organ donation and lung utilization across the world [<a href="#rid8">8</a>]; in the United States, lungs are retrieved from approximately 20 percent of cadaveric donors [<a href="#rid8">8,9</a>]. These disparities are likely due to the lung's vulnerability to potential complications that often arise before and after donor brain death such as thoracic trauma, aspiration, ventilator associated lung injury, pneumonia, and neurogenic pulmonary edema. Nonetheless, a portion of rejected donor lungs may have been suitable for transplantation [<a href="#rid8">8</a>]. Studies suggest that ex vivo lung perfusion and reconditioning may ameliorate lung injury in some cases and allow transplantation from donors previously deemed unsuitable [<a href="#rid10">10,11</a>]. Standard and extended criteria for donor lung selection and their impact on short and long-term outcomes are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4652.html" rel="external">"Lung transplantation: Donor lung procurement and preservation"</a>.)</p><p>In the early years, single lung transplantation was more frequent than bilateral transplantation. While the number of single lung transplants performed annually has remained stable, the number of bilateral transplants has consistently increased and surpassed the number of single lung procedures in 2002 (<a class="graphic graphic_figure graphicRef71574" href="/z/d/graphic/71574.html" rel="external">figure 1</a>) [<a href="#rid5">5</a>]. The choice of procedure and recipient selection are presented separately. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a>.)</p><p>The most common diseases that lead to lung transplant are interstitial lung disease (including idiopathic pulmonary fibrosis), chronic obstructive pulmonary disease, cystic fibrosis, alpha-1 antitrypsin deficiency, and idiopathic pulmonary hypertension (<a class="graphic graphic_figure graphicRef61485" href="/z/d/graphic/61485.html" rel="external">figure 2</a>) [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a>.)</p><p class="headingAnchor" id="H3"><span class="h1">ORGANIZATIONS</span><span class="headingEndMark"> — </span>Transplant organizations and organ allocation policies are influenced by medical, ethical, geographical, and political factors and systems vary from country to country. In the United States, there are three main components of the transplant system: the United Network for Organ Sharing (UNOS), the organ procurement organizations (OPOs), and the transplant centers. Their different responsibilities are reviewed here.</p><p class="headingAnchor" id="H4"><span class="h2">United Network for Organ Sharing</span><span class="headingEndMark"> — </span>UNOS is a private, non-profit organization that operates the Organ Procurement and Transplantation Network (OPTN) under a contract with the US Department of Health and Human Services. UNOS develops policies that govern the transplant system with the goal of maximizing the efficient and equitable use of organs. In addition, UNOS maintains data pertaining to the waiting list, organ matching, and transplants. All OPOs and transplant centers must be members of UNOS.</p><p class="headingAnchor" id="H5"><span class="h2">Organ procurement organizations</span><span class="headingEndMark"> — </span>OPOs are private, non-profit organizations that recover organs within their geographical territory and allocate them based on UNOS guidelines.</p><p class="headingAnchor" id="H6"><span class="h2">Lung transplant centers</span><span class="headingEndMark"> — </span>Transplant centers are the focal point of the transplant system for patients and clinicians. In the United States, many health plans have preferred provider provisions for lung transplantation, and Medicare will only cover the procedure at approved centers.</p><p class="headingAnchor" id="H7"><span class="h1">LUNG ALLOCATION</span><span class="headingEndMark"> — </span>Since March 2023, the order of patients on the waiting list for lung transplantation has been based on a lung Composite Allocation Score (CAS), which was developed to further improve waitlist mortality and provide more lung transplants to the most medically urgent candidates [<a href="#rid12">12</a>]. </p><p>The adoption of CAS is part of a new policy that utilizes an approach known as continuous distribution, in which all of the factors used for organ matching are included in a single, weighted score calculated for each lung transplant candidate and lung offer. Under the previous lung allocation system, a set of different matching classifications (eg, candidate urgency, donor compatibility, and distance between donor and transplant hospitals) were determined individually and then applied sequentially to determine lung offers.</p><p>The CAS score has a theoretical maximum score of 100 points, and has the following individual components (<a class="graphic graphic_table graphicRef59818" href="/z/d/graphic/59818.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Candidate medical urgency (ie, expected waitlist survival, maximum 25 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Likelihood of recipient survival over five years post-transplant (maximum 25 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Potential biological challenges in matching, such as the candidate’s blood type, height, or immune sensitivity (maximum 15 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the candidate was younger than age 18 years when listed for a transplant (20 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Whether the candidate was a prior living organ donor (5 points)</p><p class="bulletIndent1"><span class="glyph">●</span>Placement efficiency (based on logistics of preserving and transporting the lungs between donor and transplant hospitals, maximum 10 points)</p><p></p><p>This CAS score will be different for every offer due to the placement efficiency component. CAS replaces the previous Lung Allocation Score (LAS) for patients 12 years of age and older. An approximate CAS calculator is available on the Organ Procurement and Transplantation Network (OPTN) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Foptn.transplant.hrsa.gov%2Fdata%2Fallocation-calculators%2Flung-cas-calculator%2F&amp;token=8CWIkpM2hckDb9NZ0y5EDWzsqUo6KO%2BgV2TMBlkj%2FNBmPpE9hyQ04W5A9qLw6gcKqbw%2BP%2BY0EGXbuO9xT%2FfmWjIR5bb8OYh2NhZC8FcxZhw%3D&amp;TOPIC_ID=4659" target="_blank">website</a>. For patients under the age of 12 years, the current pediatric priority scores are incorporated into the CAS medical urgency formula in addition to the "patient access" points for candidates younger than age 18 years.</p><p>The Scientific Registry of Transplant Recipients performed two rounds of simulation modeling to assess potential effects of these changes on transplant allocation and outcomes [<a href="#rid13">13,14</a>]. The results of these analyses indicated that compared to LAS, CAS should decrease waitlist deaths, reduce median distance lungs are transported, lessen variability across OPTN regions, and increase lung allocation to the following groups: pediatric patients; urgent adult patients (LAS &gt;60); adult patients with reduced height (&lt;158 cm); patients with type O blood; and patients with the best predicted post-transplant outcomes. The actual impact of this change on lung allocation and transplant outcomes remains to be seen.</p><p class="headingAnchor" id="H8"><span class="h1">REFERRAL FOR TRANSPLANT EVALUATION</span><span class="headingEndMark"> — </span>Patients with untreatable, advanced stage lung disease are referred to regional transplant centers for evaluation. Transplant centers typically screen the medical records of referred patients before an on-site evaluation is scheduled. The transplant centers thoroughly evaluate patients to determine the appropriateness of placing them on the transplant waiting list and to collect the information from which the Lung Allocation Score is derived. The patient is registered with UNOS and the patient's profile is updated at intervals, usually every six months.</p><p class="bulletIndent1"><span class="glyph">●</span>When donor organs become available, the procuring organization contacts UNOS' national transplant communications center, UNet, by telephone or internet access. The UNet computer system runs donor/recipient matches based on blood type, size of the organ, and distance between the donor and recipient.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>UNOS then communicates the ranked match results to the OPOs to contact the transplant centers of the highest ranked patient. Once the organ is accepted, the OPO arranges transportation and the transplant surgery is scheduled.</p><p></p><p>Specifics of donor and recipient lung evaluation, selection, and management are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4658.html" rel="external">"Lung transplantation: General guidelines for recipient selection"</a> and  <a class="medical medical_review" href="/z/d/html/4664.html" rel="external">"Lung transplantation: Deceased donor evaluation"</a>.)</p><p>The type of transplant procedure and postoperative management are also discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4660.html" rel="external">"Lung transplantation: Disease-based choice of procedure"</a> and  <a class="medical medical_review" href="/z/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management"</a>.)</p><p class="headingAnchor" id="H9"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Outcome after lung transplantation can be assessed based on several different criteria: survival, quality of life, physiologic changes, and cost benefit [<a href="#rid5">5,15</a>]. Survival is perhaps the most straightforward assessment of outcome, and large registries can easily generate actuarial survival estimates based on multi-center and international data. However, other endpoints such as quality of life offer important insights into the benefits of lung transplantation.</p><p class="headingAnchor" id="H10"><span class="h2">Survival</span><span class="headingEndMark"> — </span>The International Society for Heart and Lung Transplantation (ISHLT) has maintained a registry that has accrued data on more than 64,000 recipients from over a hundred transplant centers worldwide. The Registry has generated survival estimates from these data annually that have become a benchmark for the field [<a href="#rid5">5</a>].</p><p>According to the ISHLT registry report, the median survival for adult recipients since 2010 is 6.7 years, but bilateral lung recipients appear to have a better median survival than single lung recipients (7.8 versus 4.8 years, respectively; for a figure showing updated information, please see the International Society for Heart and Lung Transplantation 2019 slide set "Overall Lung and Adult Lung Transplantation Statistics," slide titled Adult Lung Transplantation Kaplan-Meier Survival by Procedure Type at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fishltregistries.org%2Fregistries%2Fslides.asp&amp;token=MDXro05ivebLvlMrwIKPNZNOwMeCI5s%2B6UW2zMxK6Hf3rsDg0xIG3r0yhm70Bo3k&amp;TOPIC_ID=4659" target="_blank">ISHLT Registry</a>) [<a href="#rid16">16</a>].</p><p>However, it is unclear if this survival advantage is directly related to the choice of operation or to the underlying recipient characteristics that influence this choice. A study that evaluated the impact of recipient age and operation performed on the survival of recipients with pulmonary fibrosis, found that single lung recipients younger than 60 years of age had a survival advantage over bilateral recipients in the same age group [<a href="#rid17">17</a>].</p><p>The impact of underlying diagnosis on survival after transplantation has been evaluated extensively (<a class="graphic graphic_figure graphicRef57297" href="/z/d/graphic/57297.html" rel="external">figure 3</a>) [<a href="#rid5">5,18,19</a>]. The underlying diagnosis is often linked to age. In addition, certain diagnoses carry higher risks of operative complications and primary graft dysfunction. Nonetheless, recipients with COPD have the best one-year survival, but a lower ten-year survival compared to those with cystic fibrosis (CF), idiopathic pulmonary arterial hypertension, and alpha-1 antitrypsin deficiency [<a href="#rid5">5</a>]. Recipients with IPAH have the lowest one-year survival, but their ten-year survival approaches those with CF. Lastly, those with idiopathic interstitial pneumonia or COPD have a lower ten-year survival compared to others.</p><p>The Registry has also reported that one-year survival between the years 2010 and 2017 was significantly better than the two previous eras (1992 to 2001 and 2002 to 2009; For a figure showing updated information, please see the International Society for Heart and Lung Transplantation 2019 slide set "Overall Lung and Adult Lung Transplantation Statistics," slide titled Adult Lung Transplantation Kaplan-Meier Survival by Era [Transplants: January 1992 to June 2017] at: <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fishltregistries.org%2Fregistries%2Fslides.asp&amp;token=MDXro05ivebLvlMrwIKPNZNOwMeCI5s%2B6UW2zMxK6Hf3rsDg0xIG3r0yhm70Bo3k&amp;TOPIC_ID=4659" target="_blank">ISHLT Registry</a>). However, the five-year survival of patients alive at one-year post-transplant was not different between the 2002 to 2007 and 2008 to 2013 eras, suggesting that management strategies have been more effective at reducing early complications than later ones, possibly due to refinements in surgical techniques and postoperative care [<a href="#rid5">5</a>]. In contrast, survival beyond the first year is primarily affected by chronic rejection and infections [<a href="#rid20">20,21</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Causes of death</span><span class="headingEndMark"> — </span>Primary graft dysfunction (PGD), a form of ARDS/diffuse alveolar damage (DAD), which occurs in the early hours to days after transplant, is the leading cause of death in the first 30 days after transplantation, accounting for more than 20 percent of deaths [<a href="#rid5">5,22</a>]. The incidence of PGD has varied depending on the definition used [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">"Primary lung graft dysfunction"</a>.)</p><p>A grading system for PGD incorporates the PaO<sub>2</sub>/FiO<sub>2</sub> ratio and chest radiograph findings [<a href="#rid23">23</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>PGD grade 0: PaO<sub>2</sub>/FiO<sub>2</sub> &gt;300 and no pulmonary edema on chest radiograph</p><p class="bulletIndent1"><span class="glyph">●</span>PGD grade 1: PaO<sub>2</sub>/FiO<sub>2</sub> &gt;300 and pulmonary edema on chest radiograph</p><p class="bulletIndent1"><span class="glyph">●</span>PGD grade 2: PaO<sub>2</sub>/FiO<sub>2</sub> = 200 to 300 and pulmonary edema on chest radiograph</p><p class="bulletIndent1"><span class="glyph">●</span>PGD grade 3: PaO<sub>2</sub>/FiO<sub>2</sub> &lt;200 and pulmonary edema on chest radiograph</p><p></p><p>The effect of PGD on survival is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">"Primary lung graft dysfunction", section on 'Survival'</a>.)</p><p>Chronic lung allograft dysfunction (CLAD), which manifests as BOS or restrictive allograft syndrome (RAS), is the leading cause of mortality after the first year, accounting for 20 to 30 percent of deaths [<a href="#rid5">5</a>]. This remains the primary obstacle to better long-term outcomes after lung transplantation. The incidence of BOS approaches 50 percent within five years of transplantation [<a href="#rid5">5</a>]. Survival three years after the onset of BOS is only 50 percent, and drops to 30 to 40 percent at five years. Superimposed infections and malignancies due to immunosuppressive therapy often further complicate the course. (See  <a class="medical medical_review" href="/z/d/html/4654.html" rel="external">"Chronic lung allograft dysfunction: Bronchiolitis obliterans syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/128271.html" rel="external">"Chronic lung allograft dysfunction: Restrictive allograft syndrome"</a>.)</p><p>Infectious complications remain a leading cause of death at all time points after lung transplantation, accounting for 35 percent of deaths in the first year and 20 percent of deaths thereafter [<a href="#rid5">5</a>]. Bacterial bronchitis and pneumonia are most common, but fungi, cytomegalovirus, community acquired respiratory viruses, and mycobacteria all contribute to the overall burden [<a href="#rid24">24-27</a>]. (See  <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">"Bacterial infections following lung transplantation"</a> and  <a class="medical medical_review" href="/z/d/html/8313.html" rel="external">"Prevention of cytomegalovirus infection in lung transplant recipients"</a>.)</p><p>Malignancy accounts for a small percentage of mortality in the first year after transplantation; beyond the first year, 7 to 10 percent of all deaths are due to cancer. Nonmelanoma skin cancer is the most prevalent malignancy overall, but posttransplant lymphoproliferative disease (PTLD) is the most common malignancy in the first year after transplant and second most common overall [<a href="#rid5">5</a>]. Other malignancies include colon and breast cancer. A study from Israel found an increased incidence of Kaposi's sarcoma and transitional cell carcinoma of the bladder (4 percent each) in addition to non-melanotic skin cancer and PTLD [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/z/d/html/4656.html" rel="external">"Noninfectious complications following lung transplantation", section on 'Malignancy'</a>.)</p><p class="headingAnchor" id="H12"><span class="h2">Quality of life</span><span class="headingEndMark"> — </span>After the postoperative recovery, most recipients are able to resume an unencumbered lifestyle. Over 80 percent report no activity limitations and almost 40 percent of five-year survivors are working at least part-time [<a href="#rid5">5</a>]. Furthermore, multiple studies have documented that lung transplantation confers significant benefits in health-related quality of life [<a href="#rid29">29,30</a>]. One study showed comparable health-related quality of life results between lung transplant recipients and a normative sample of healthy people, with the exception of the social functioning domain [<a href="#rid31">31</a>].</p><p>Postoperative complications hamper this improvement in quality of life. One study showed that PGD grade 3 attenuated the improvement in health-related quality of life and that this was related to the duration of mechanical ventilation [<a href="#rid32">32</a>]. Likewise, postoperative delirium is associated with attenuated improvement in health-related quality of life [<a href="#rid33">33</a>]. Recipients who have developed BOS report more physical restrictions and depressive and anxiety symptoms than those who have not and have decrements in health-related quality of life compared to their pre-BOS evaluation [<a href="#rid31">31,34,35</a>]. A study that validated a lung transplant quality of life survey demonstrated that recipients with severe CLAD reported significantly worse health-related quality of life than those without CLAD [<a href="#rid36">36</a>]. Similarly, infections and episodes of acute rejection have a negative impact on health-related quality of life [<a href="#rid31">31</a>]. Nonetheless, even if the survival advantage itself is modest, the prospect of improving quality of life and quality-adjusted survival is often the motivation for transplantation for many recipients.</p><p class="headingAnchor" id="H2810122726"><span class="h2">Retransplantation</span><span class="headingEndMark"> — </span>Retransplantation among lung transplant recipients is infrequent and accounts for approximately 4 percent of lung transplant procedures [<a href="#rid5">5</a>]. Survival after first retransplant operation is 75 percent at 1 year, 36 percent at 5 years, and 21 percent at 10 years [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/4651.html" rel="external">"Lung transplantation: Procedure and postoperative management", section on 'Retransplantation'</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Cost and cost-effectiveness</span><span class="headingEndMark"> — </span>Lung transplantation is an expensive treatment with perhaps only modest improvements in quality-adjusted survival. Nonetheless, there is no social consensus on the monetary value of a quality-adjusted life year gained through lung transplantation or any other treatment.</p><p>A relatively small number of studies have examined the cost and the cost-effectiveness of lung transplantation [<a href="#rid38">38,39</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>In a study of lung transplantations performed at one center between May 2005 and June 2009, median charges for the transplantation admission were $153,995 for patients with lung allocation scores (LAS) in the three lower quartiles, compared with $276,668 for those with LAS scores in the highest quartile [<a href="#rid38">38</a>]. However, no difference between the LAS quartiles was noted in the charges for the first year, when the transplantation admission charges were excluded.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a study that examined the index hospitalization charges of patients who required extracorporeal membrane oxygenation (ECMO) between 2000 and 2011, median charges for lung transplant recipients who required ECMO were US$780,391 compared with US$324,279 for those who did not [<a href="#rid39">39</a>].</p><p></p><p>Wage effects are not included in the cost-effectiveness analysis in most studies, and if recipients returned to work, this would be an obvious asset. Employment after lung transplantation varies; this is in part dependent on whether the recipient was already at or past retirement age. In an analysis of the ISHLT registry, approximately 13 percent of lung recipients were working at one year after transplant and 18 percent after 5 years [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H3900683784"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/122278.html" rel="external">"Society guideline links: Lung transplantation"</a>.)</p><p class="headingAnchor" id="H434014645"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, “The Basics” and “Beyond the Basics.” The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on “patient info” and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/87302.html" rel="external">"Patient education: Lung transplant (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H1828937600"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/131727.html" rel="external">"Patient perspective: Lymphangioleiomyomatosis (LAM)"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The number of lung transplants performed each year has grown steadily since 1985, although further increases in this number appear to be limited by organ availability. The proportion of bilateral lung transplants has increased and surpassed that of single lung transplants (<a class="graphic graphic_figure graphicRef71574" href="/z/d/graphic/71574.html" rel="external">figure 1</a>). (See <a class="local">'Activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The most common diseases that lead to lung transplant are chronic obstructive pulmonary disease (COPD), interstitial lung disease (ILD), cystic fibrosis, alpha-1 antitrypsin deficiency, and idiopathic pulmonary arterial hypertension (IPAH) (<a class="graphic graphic_figure graphicRef61485" href="/z/d/graphic/61485.html" rel="external">figure 2</a>). (See <a class="local">'Activity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Responsibility for recipient evaluation, waiting list management, and matching of donor organs with recipients is shared by three organizations: United Network for Organ Sharing (UNOS), Organ Procurement Organizations (OPOs), and lung transplant centers. (See <a class="local">'Organizations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung allocation to patients on the waiting list has been based on a Lung "Composite Allocation Score" since March 2023. This score includes a measure of urgency of need for transplant, a post-transplant likelihood of survival measure, a biologic compatibility measure, and a placement efficiency measure. (See <a class="local">'Lung allocation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Primary graft dysfunction (PGD) and infections are the major causes of death in the first year post transplant; chronic graft dysfunction due to bronchiolitis obliterans syndrome is the major cause of death after the first year. (See <a class="local">'Outcomes'</a> above and  <a class="medical medical_review" href="/z/d/html/4663.html" rel="external">"Primary lung graft dysfunction"</a> and  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The underlying lung disease influences mortality post-transplant: first year mortality is lowest for COPD and highest for IPAH. In contrast, mortality at 10 years is highest for COPD and idiopathic interstitial pneumonia and lowest for cystic fibrosis and alpha-1 antitrypsin (<a class="graphic graphic_figure graphicRef57297" href="/z/d/graphic/57297.html" rel="external">figure 3</a>). (See <a class="local">'Outcomes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lung transplant is an expensive treatment that provides only modest gains in quality adjusted life years. (See <a class="local">'Outcomes'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">HARDY JD, WEBB WR, DALTON ML Jr, WALKER GR Jr. LUNG HOMOTRANSPLANTATION IN MAN. JAMA 1963; 186:1065.</a></li><li><a class="nounderline abstract_t">Reitz BA, Wallwork JL, Hunt SA, et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306:557.</a></li><li><a class="nounderline abstract_t">Toronto Lung Transplant Group. Unilateral lung transplantation for pulmonary fibrosis. N Engl J Med 1986; 314:1140.</a></li><li><a class="nounderline abstract_t">Cooper JD, Patterson GA, Grossman R, Maurer J. Double-lung transplant for advanced chronic obstructive lung disease. Am Rev Respir Dis 1989; 139:303.</a></li><li><a class="nounderline abstract_t">Chambers DC, Perch M, Zuckermann A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics. J Heart Lung Transplant 2021; 40:1060.</a></li><li><a class="nounderline abstract_t">Shafer TJ, Wagner D, Chessare J, et al. US organ donation breakthrough collaborative increases organ donation. Crit Care Nurs Q 2008; 31:190.</a></li><li><a class="nounderline abstract_t">Valapour M, Lehr CJ, Skeans MA, et al. OPTN/SRTR 2019 Annual Data Report: Lung. Am J Transplant 2021; 21 Suppl 2:441.</a></li><li><a class="nounderline abstract_t">Riddell P, Egan JJ. International donor conversion rates for lung transplantation need to be standardised. Lancet Respir Med 2015; 3:909.</a></li><li><a class="nounderline abstract_t">Mooney JJ, Hedlin H, Mohabir PK, et al. Lung Quality and Utilization in Controlled Donation After Circulatory Determination of Death Within the United States. Am J Transplant 2016; 16:1207.</a></li><li><a class="nounderline abstract_t">Ingemansson R, Eyjolfsson A, Mared L, et al. Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo. Ann Thorac Surg 2009; 87:255.</a></li><li><a class="nounderline abstract_t">Cypel M, Rubacha M, Yeung J, et al. Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation. Am J Transplant 2009; 9:2262.</a></li><li class="breakAll">OPTN Lung CAS Policy Notice: https://optn.transplant.hrsa.gov/media/b13dlep2/policy-notice_lung_continuous-distribution.pdf (Accessed on May 07, 2023).</li><li class="breakAll">SRTR continuous distribution simulations for lung transplant  round 1: https://optn.transplant.hrsa.gov/media/4450/lu2020_05_cont_distn_srtr_1.pdf (Accessed on May 07, 2023).</li><li class="breakAll">SRTR continuous distribution simulations for lung transplant  round 2: https://optn.transplant.hrsa.gov/media/4646/lu2021_01_cont_distn_report_final.pdf (Accessed on May 07, 2023).</li><li><a class="nounderline abstract_t">Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis 2017; 9:2684.</a></li><li><a class="nounderline abstract_t">Chambers DC, Cherikh WS, Harhay MO, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. J Heart Lung Transplant 2019; 38:1042.</a></li><li><a class="nounderline abstract_t">Meyer DM, Edwards LB, Torres F, et al. Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis. Ann Thorac Surg 2005; 79:950.</a></li><li><a class="nounderline abstract_t">Liu V, Zamora MR, Dhillon GS, Weill D. Increasing lung allocation scores predict worsened survival among lung transplant recipients. Am J Transplant 2010; 10:915.</a></li><li><a class="nounderline abstract_t">Titman A, Rogers CA, Bonser RS, et al. Disease-specific survival benefit of lung transplantation in adults: a national cohort study. Am J Transplant 2009; 9:1640.</a></li><li><a class="nounderline abstract_t">Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005. J Heart Lung Transplant 2005; 24:956.</a></li><li><a class="nounderline abstract_t">Yusen RD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure. J Heart Lung Transplant 2015; 34:1264.</a></li><li><a class="nounderline abstract_t">Diamond JM, Arcasoy S, Kennedy CC, et al. Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1104.</a></li><li><a class="nounderline abstract_t">Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2017; 36:1097.</a></li><li><a class="nounderline abstract_t">Lehto JT, Koskinen PK, Anttila VJ, et al. Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients. Transpl Int 2005; 18:562.</a></li><li><a class="nounderline abstract_t">Solé A, Morant P, Salavert M, et al. Aspergillus infections in lung transplant recipients: risk factors and outcome. Clin Microbiol Infect 2005; 11:359.</a></li><li><a class="nounderline abstract_t">Malouf MA, Glanville AR. The spectrum of mycobacterial infection after lung transplantation. Am J Respir Crit Care Med 1999; 160:1611.</a></li><li><a class="nounderline abstract_t">Glanville AR, Scott AI, Morton JM, et al. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant 2005; 24:2114.</a></li><li><a class="nounderline abstract_t">Amital A, Shitrit D, Raviv Y, et al. Development of malignancy following lung transplantation. Transplantation 2006; 81:547.</a></li><li><a class="nounderline abstract_t">Singer LG, Chowdhury NA, Faughnan ME, et al. Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation. Am J Respir Crit Care Med 2015; 192:965.</a></li><li><a class="nounderline abstract_t">Singer JP, Katz PP, Soong A, et al. Effect of Lung Transplantation on Health-Related Quality of Life in the Era of the Lung Allocation Score: A U.S. Prospective Cohort Study. Am J Transplant 2017; 17:1334.</a></li><li><a class="nounderline abstract_t">Kugler C, Fischer S, Gottlieb J, et al. Health-related quality of life in two hundred-eighty lung transplant recipients. J Heart Lung Transplant 2005; 24:2262.</a></li><li><a class="nounderline abstract_t">Kolaitis NA, Gao Y, Soong A, et al. Primary graft dysfunction attenuates improvements in health-related quality of life after lung transplantation, but not disability or depression. Am J Transplant 2021; 21:815.</a></li><li><a class="nounderline abstract_t">DeBolt CL, Gao Y, Sutter N, et al. The association of post-operative delirium with patient-reported outcomes and mortality after lung transplantation. Clin Transplant 2021; 35:e14275.</a></li><li><a class="nounderline abstract_t">Gross CR, Savik K, Bolman RM 3rd, Hertz MI. Long-term health status and quality of life outcomes of lung transplant recipients. Chest 1995; 108:1587.</a></li><li><a class="nounderline abstract_t">van Den BERG JW, Geertsma A, van Der BIJ W, et al. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med 2000; 161:1937.</a></li><li><a class="nounderline abstract_t">Singer JP, Soong A, Chen J, et al. Development and Preliminary Validation of the Lung Transplant Quality of Life (LT-QOL) Survey. Am J Respir Crit Care Med 2019; 199:1008.</a></li><li><a class="nounderline abstract_t">Clausen ES, Weber JM, Palmer SM. Predicting Survival for Lung Retransplantation Patients at One and Five Years. J Heart Lung Transplant 2019; 38:S225.</a></li><li><a class="nounderline abstract_t">Arnaoutakis GJ, Allen JG, Merlo CA, et al. Impact of the lung allocation score on resource utilization after lung transplantation in the United States. J Heart Lung Transplant 2011; 30:14.</a></li><li><a class="nounderline abstract_t">Hayanga JWA, Shigemura N, Aboagye JK, et al. ECMO Support in Lung Transplantation: A Contemporary Analysis of Hospital Charges in the United States. Ann Thorac Surg 2017; 104:1033.</a></li></ol></div><div id="topicVersionRevision">Topic 4659 Version 30.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14061414" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : LUNG HOMOTRANSPLANTATION IN MAN.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6799824" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3515192" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Unilateral lung transplantation for pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643898" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Double-lung transplant for advanced chronic obstructive lung disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34446355" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-eighth adult lung transplantation report - 2021; Focus on recipient characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574367" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : US organ donation breakthrough collaborative increases organ donation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33595190" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : OPTN/SRTR 2019 Annual Data Report: Lung.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679015" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : International donor conversion rates for lung transplantation need to be standardised.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26844673" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Lung Quality and Utilization in Controlled Donation After Circulatory Determination of Death Within the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19101308" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Clinical transplantation of initially rejected donor lungs after reconditioning ex vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663886" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663886" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663886" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19663886" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Normothermic ex vivo perfusion prevents lung injury compared to extended cold preservation for transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28932576" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Outcomes after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31548030" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15734411" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Impact of recipient age and procedure type on survival after lung transplantation for pulmonary fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20121747" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Increasing lung allocation scores predict worsened survival among lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19656145" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Disease-specific survival benefit of lung transplantation in adults: a national cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16102428" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Registry of the International Society for Heart and Lung Transplantation: twenty-second official adult lung and heart-lung transplant report--2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26454740" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The Registry of the International Society for Heart and Lung Transplantation: Thirty-second Official Adult Lung and Heart-Lung Transplantation Report--2015; Focus Theme: Early Graft Failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28802530" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Report of the International Society for Heart and Lung Transplantation Working Group on Primary Lung Graft Dysfunction, part II: Epidemiology, risk factors, and outcomes-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28942784" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15819805" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bronchoscopy in the diagnosis and surveillance of respiratory infections in lung and heart-lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15819861" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Aspergillus infections in lung transplant recipients: risk factors and outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10556129" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The spectrum of mycobacterial infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364859" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16495802" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Development of malignancy following lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26131729" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Effects of Recipient Age and Diagnosis on Health-related Quality-of-Life Benefit of Lung Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27743488" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Effect of Lung Transplantation on Health-Related Quality of Life in the Era of the Lung Allocation Score: A U.S. Prospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16364880" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Health-related quality of life in two hundred-eighty lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32794295" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Primary graft dysfunction attenuates improvements in health-related quality of life after lung transplantation, but not disability or depression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33682171" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The association of post-operative delirium with patient-reported outcomes and mortality after lung transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7497766" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Long-term health status and quality of life outcomes of lung transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10852770" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30303408" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Development and Preliminary Validation of the Lung Transplant Quality of Life (LT-QOL) Survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Predicting Survival for Lung Retransplantation Patients at One and Five Years</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20869886" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Impact of the lung allocation score on resource utilization after lung transplantation in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28688632" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : ECMO Support in Lung Transplantation: A Contemporary Analysis of Hospital Charges in the United States.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
